{ "@context": "https://orbyd.app/schemas/dossier.v1.json", "ticker": "ABX", "name": "Abacus Global Management, Inc.", "url": "https://orbyd.app/dossiers/ABX/", "json_url": "https://orbyd.app/dossiers/ABX.json", "status": "DORMANT", "current_conviction": "LOW", "graded_conviction": null, "archetype": { "code": "a4", "n": 4 }, "current_thesis": "Life-settlements franchise bolted the RWA-tokenization narrative (100+ policies on-chain, $224B TAM) onto a Q1 beat and a raised FY adj-EPS guide, but shares rejected the $12.44 high with a −7.3% sell-the-news day into a binary ~2026-08-06 Q2 print — narrative accelerating, tape not yet confirming.", "invalidation_trigger": "A weekly close below $10 breaks the year-long uptrend base and the low end of the $10–15 analyst target range; secondarily, the ~2026-08-06 Q2 print missing the $0.24–0.26 adjusted-EPS guide, or the tokenization rollout stalling with no named custody partner and the RWA theme rotating to SATURATED.", "catalyst_date": "2026-08-06", "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "medtech-diagnostics", "small-cap-value-rotation" ], "tags": [], "sources": [], "notes": [ "Ticker collision: ABX = Abacus Global Management (NYSE, life settlements). NOT Barrick Gold (legacy ABX → now GOLD) nor Abaxx Technologies (ABXXF). Prior rare-earths/critical-materials theme tag was a mis-tag; correct it if it reappears.", "Coventry First defamation suit proceeding in U.S. District Court (motion to dismiss denied 2026-06-26) — litigation/headline overhang.", "Price action: tapped 52w high $12.44 week of 07-07, then −7.34% to $11.11 on 07-10. Failed breakout — want a higher-low reclaim of $11.60–12.00 before treating strength as confirmation.", "Q2 2026 earnings ~2026-08-06; guided adj EPS $0.24–0.26, FY adj EPS $1.00–1.05. Binary print — avoid fresh size into it.", "Tokenization announced 2026-07-07: 100+ policies on-chain, full portfolio targeted on-chain by year-end 2026, $224B secondary-market TAM. Rollout promise with no revenue attached yet — narrative, not numbers.", "Ticker collision: ABX = Abacus Global Management (NYSE, life settlements). NOT Barrick Gold (legacy ABX → now GOLD) nor Abaxx Technologies (ABXXF). Correct any rare-earths/critical-materials/medtech mis-tag if it reappears.", "Analyst tape: Grondahl reiterated Buy $13.50 (2026-06-29); Piper Sandler Neutral, PT raised to $13 (2026-07-13); avg target ~$13.3–13.7, high $15, low $10.", "Failed breakout: $12.44 52w high week of 07-07, then −7.34% to $11.11 (07-10). Want a higher-low reclaim of $11.60–12.00 before treating strength as confirmation." ], "body_markdown": "## Current Thesis\nAbacus is a cash-generating life-settlements franchise that attached itself to the real-world-asset (RWA) tokenization narrative on 2026-07-07, claiming 100+ in-force policies already on-chain and the full portfolio targeted on-chain by year-end 2026 against a secondary market it sizes at $224B. The financials underneath are real: Q1 2026 (reported 2026-05-07) grew revenue 35% YoY and forced a full-year guidance raise. What is missing is price confirmation. Shares tapped a 52-week high of $12.44 the week of the announcement and reversed −7.34% to $11.11 on 2026-07-10, a sell-the-news rejection off the high. With the ~2026-08-06 Q2 print now roughly eleven sessions out, this reads as a wait-for-the-binary setup rather than a chase, and a fresh entry here is a probe at best.\n\n## Bull Case\n- Q1 2026 (reported 2026-05-07): revenue +35% YoY to $59.4M; GAAP net income +59% to $7.3M; adjusted net income +17% to $20.1M; adjusted EBITDA +33.3% to $32.7M; operating cash flow $91.7M — a real cash-flow book, not a pre-revenue story.\n- Same-day guidance raise (2026-05-07): FY2026 adjusted net income $100–106M and adjusted EPS $1.00–1.05, above prior consensus; Q2 adjusted EPS guided $0.24–0.26.\n- Tokenization catalyst (2026-07-07): 100+ policies on-chain with verifiable chain-of-title, lien, and cash-flow records; entire balance-sheet portfolio targeted on-chain by year-end 2026, addressing a $224B secondary life-insurance TAM. This is the narrative capable of re-rating a legacy specialty-finance multiple.\n- Analyst coverage broadening: Michael Grondahl reiterated Buy with a $13.50 target on 2026-06-29; Piper Sandler raised its target to $13 on 2026-07-13. Consensus leans Strong Buy with an average target near $13.3–13.7, high $15, low $10.\n- Longer-term structure intact: year-long uptrend off the $4.80 52-week low, still trading above the 200-day; market cap ~$1.07B.\n\n## Bear Case\n- The $12.44 high printed on the tokenization news, then faded −7.34% to $11.11 on 2026-07-10 — the announcement marked a local top, not a launchpad.\n- Tokenization is announced, not monetized. No revenue is attached, no named custody or institutional partner has been disclosed, and on-chain transfer of life-settlement interests carries unresolved regulatory questions.\n- Piper Sandler's 2026-07-13 note captures the ambivalence: a higher $13 target paired with a Neutral rating is a valuation nod without a conviction endorsement.\n- Earnings-quality gap: Q1 adjusted net income $20.1M versus GAAP $7.3M. Life settlements is mark-to-model on actuarial assumptions, and a wide adjusted-to-GAAP spread invites scrutiny of stated book value.\n- Binary Q2 print ~2026-08-06 into a rejected high on a thin-float $1.07B small-cap; the $0.24–0.26 adjusted-EPS guide is the bar and a miss round-trips the recent range fast.\n- Litigation overhang: the defamation action against Coventry First and chairman Alan Buerger advanced when the court denied Coventry's motion to dismiss on 2026-06-26 — ongoing headline and management-distraction risk.\n\n## Setup & Price Structure\n- Last reference: $11.11 (2026-07-10 close), −7.34% on the day from a $11.99 prior close; more recent quotes are not in hand, so treat the structure read as provisional into earnings.\n- 52-week range $4.80–$12.44; price sits in the upper third and above the 200-day, but freshly rejected from the high.\n- Reclaim level: a higher-low base followed by a push back through $11.60–12.00 would turn the failed breakout into a valid continuation. Until that happens, strength is unconfirmed.\n- Downside pivot: $10 is the confluence of the rising base and the low end of the analyst target band; losing it on a weekly basis breaks the uptrend thesis.\n- Thin coverage (roughly 5–9 analysts) and a ~$1.07B cap mean light volume can push the tape hard in either direction.\n\n## Catalyst Calendar (next 30 days)\n\n- Ongoing through the period: tokenization rollout milestones toward the year-end-2026 \"full portfolio on-chain\" target; a named custody or institutional partner would be the first real monetization signal.\n\n## Elapsed catalysts\n\n- ~2026-08-06 (est.): Q2 2026 earnings. Guided adjusted EPS $0.24–0.26; FY adjusted EPS $1.00–1.05. Binary event — the tokenization narrative gets its first numbers-adjacent update here. *(passed 3d ago)*\n- Ongoing: Coventry First defamation litigation in U.S. District Court following the 2026-06-26 denial of the motion to dismiss; any procedural headline is a swing factor on light float. *(passed 44d ago)*\n\n## What Would Change Our Mind\n- Bull confirmation: a weekly close back above $12.00 on expanding volume, ideally paired with a tokenization monetization event (named partner, on-chain volumes, or disclosed fee economics), would reframe the failed breakout as a base-and-go worth sizing.\n- Bear confirmation: a weekly close below $10 breaks the year-long base; a Q2 miss versus the $0.24–0.26 guide, or a stalled rollout with the RWA theme rotating to SATURATED, would flip this from accelerating to broken.\n- Neutralizing outcome: a soft-but-in-line Q2 print that neither monetizes tokenization nor breaks structure keeps this a low-conviction name to stand aside on until a cleaner setup forms.\n\n## Correlation Notes\n- RWA-tokenization narrative: trades with sentiment toward on-chain real-world assets; a broad crypto/RWA risk-off drains the premium leg of this story regardless of the underlying cash flows.\n- Specialty-finance / life-settlements: sensitive to long-end rates and actuarial-assumption scrutiny; higher discount rates compress the mark-to-model value of the policy book.\n- Small-cap liquidity: thin float and light analyst coverage tie the name to small-cap risk appetite (IWM-style rotation) more than to any large-cap financial index.", "first_seen": "2026-07-07", "last_analyzed": "2026-07-26T11:14:38+00:00", "last_synthesized": "2026-07-26", "last_update_source": "watchlist_research", "license": "Content © orbyd. Cite the canonical URL." }